New combo therapy shows promise for aggressive lung cancer in japanese patients
NCT ID NCT06812260
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug (HLX10) that helps the immune system fight cancer, combined with standard chemotherapy, in 26 Japanese patients with extensive-stage small cell lung cancer that has not been treated before. The goal is to see if the combination shrinks tumors and improves survival. Researchers will also monitor side effects and how the drug moves through the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCLC, EXTENSIVE STAGE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kansai Medical University Hospital Department of Respiratory Oncology
Hirakata, Osaka, Japan